登录新浪财经APP 搜索【信披】查看更多考评等级 董秘回答(长春高新SZ000661)： 您好，经营情况请关注公司定期报告等，对于相关新产品公司会根据政策要求、行业、市场等情况合理 确定销售政策，目前暂时无法预测未来相关情况；控股股东股权结构变化是基于优化国有企业资源配置 方面做出的，不会对公司的正常经营活动产生影响，未来如有其他达到信息披露标准的情况公司会履行 信息披露义务。谢谢！查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 投资者提问： 董秘好！目前省联盟已对长效生长激素集采，降价明显，随着竞品公司同类产品出现，大概何时全国性 的长效生长激素集采，届时对长春高新的净利润会产生多大的影响（会腰斩甚至脚斩吗），那个时候长 春高新的非生长激素产品能及时补充这个利润缺口吗，其痛风药何时进入医保，痛风药能产生多大的营 收和利润？近段时间，长春高新控股股东百分之十九的股权变动，新进入的新区产投，能对长春高新有 多大的精准资源支撑 ...

对于应披露的信息我们会按照法律法规要求履行披露义务，谢谢！查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 公司请你来做董秘不是只让你来回复谢谢你的关注的，如果只是这样回复的话，董秘这个位置谁都能 做，请重视股东诉求，告知近期路演场次数量，要求对董秘路演工作做强制指标考核 董秘回答(长春高新SZ000661)： 投资者提问： ...

来源：瑞恩资本RyanbenCapital 中国企业赴香港上市，需要取得中国证监会的备案通知书。根据港交所上市规则，中国企业需在上市聆 讯审批日期至少4个营业日之前提交"备案通知书"。只有通过港交所的上市聆讯，企业才可以在港交所 挂牌上市。 本周(2025年11月10日至11月14日)中国证监会国际司共对10家企业(全部在香港上市)出具境外发行上市 备案补充材料要求，具体如下：微亿制造、融泰药业、华恒生物、魔视智能、望圆科技、晶晨半导体、 长春高新、英派药业、普源精电、艾米森。 微亿制造 请你公司补充说明以下事项，请律师核查并出具明确的法律意见： 一、请说明备案材料对控股股东认定结果不一致的原因及认定标准，并就控股股东的认定情况出具明确 结论性意见。 二、请说明国资管理程序办理进展。 三、请说明最近12个月内新增股东入股价格的合理性，该等入股价格之间存在差异的原因，是否存在利 益输送。 四、请按照《监管规则适用指引——境外发行上市类第2号：备案材料内容和格式指引》要求说明本次 发行上市方案，备案材料及招股说明书关于发行上市方案内容不一致的原因。 七、请说明发行人及下属公司经营范围涉及广告制作、发布、设计、代理 ...

今年9月底，公司向港交所递交主板上市申请，拟在"A+H"两地上市。根据招股书，长春高新IPO募资主要用于创新管线研发、潜在全球合作及共同开 发、海外化市场推进、加强公司销售及营销能力等。 值得关注的是，Wind数据显示，截至2025年第三季度末，超达集团持有长春高新18.69%的股份，累计质押股数约3803万股，占公司总股本的9.32%。证监 会要求该公司进一步评估质押对控制权稳定性的影响。此外，针对控股股东上层投资人吉林省信政基金合伙企业（有限合伙）的穿透情况、历史股权变动 合规性及募集资金用途、下属子公司开展相关业务及具体运营情况等问题，证监会要求长春高新进行补充说明。 长春高新发布控股股东股权结构发生变更的公告 编者按：拆解企业招股、估值、上市表现，以专业视角记录资本脉动。投资时间网携手标点财经联袂锻造"解码港股IPO"特别策划，深度探寻每一次资本 浪潮背后的机遇与逻辑，敬请关注。 投资时间网、标点财经研究员 董琳 在医药行业快速变革的背景下，"东北药茅"——长春高新技术产业（集团）股份有限公司（下称长春高新，000661.SZ）控股股东股权划转事宜于日前落 定。 长春高新发布公告称，公司控股股东长春超 ...

Core Viewpoint - Changchun High-tech's stock has experienced a decline in recent trading sessions, with significant net outflows of capital and a decrease in both revenue and net profit year-on-year [1][2]. Financial Performance - For the period from January to September 2025, Changchun High-tech reported operating revenue of 9.807 billion yuan, a year-on-year decrease of 5.60% [2]. - The net profit attributable to shareholders was 1.165 billion yuan, reflecting a substantial year-on-year decline of 58.23% [2]. Stock Market Activity - On November 21, Changchun High-tech's stock price fell by 2.01%, trading at 99.65 yuan per share, with a total market capitalization of 40.651 billion yuan [1]. - The stock has seen a year-to-date increase of 2.86%, but has declined by 4.69% over the last five trading days and 15.44% over the last 20 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.63% to 104,100, while the average number of circulating shares per person increased by 4.85% to 3,840 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the third-largest shareholder, increasing its holdings by 1.307 million shares [3]. Dividend Distribution - Since its A-share listing, Changchun High-tech has distributed a total of 4.791 billion yuan in dividends, with 3.259 billion yuan distributed over the past three years [3].

Group 1 - The core point of the announcement is the change in the equity structure of the controlling shareholder, Changchun Chaoda Investment Group, which is aimed at optimizing the resource allocation of state-owned enterprises [1][2]. - Before the change, Longxiang Group held 100% of the shares in Chaoda Group. After the change, Longxiang Group holds 81% and New District Industrial Investment Group holds 19% of Chaoda Group [2]. - The change in the equity structure of the controlling shareholder will not affect the number of shares or the shareholding ratio held by the company, nor will it change the controlling shareholder or actual controller of the company [3].

Group 1 - Changchun High-tech's controlling shareholder, Changchun Chaoda Investment Group, has undergone a change in its equity structure, with 19% of its shares being transferred to Changchun New Area Industrial Investment Group [2] - The transfer of shares is part of an internal optimization of state-owned assets as decided by the Changchun New Area State-owned Assets Supervision and Administration Bureau [2] - Despite the changes, the controlling position of Changchun Chaoda remains unchanged, with the actual controller still being the New Area State-owned Assets Bureau [2] Group 2 - In 2023, Changchun High-tech has made significant progress in the innovative drug sector, including the launch of the first domestic innovative biological agent for acute gouty arthritis [3] - The company has also established a partnership with Denmark's ALK-Abello A/S for allergen-specific immunotherapy products, expanding its product pipeline in the respiratory allergy field [3] - The company is focusing its core resources on promoting new products like Jinbeixin and Meishiya, aiming to cultivate these as new profit growth points [3]

Core Viewpoint - Changchun Gaoxin announced a change in the shareholding structure of its controlling shareholder, Changchun Chaoda Investment Group, and has received a new business license from the Changchun New District branch of the Changchun Market Supervision Administration [2] Group 1 - The company has recently been notified of the change in the shareholding structure of its controlling shareholder [2] - The new business license has been issued by the relevant regulatory authority [2]

Core Viewpoint - Changchun Gaoxin (000661.SZ) announced a restructuring of its shareholding in ChaoDa Group, with 19% of the shares being transferred from Longxiang Investment Holding Group to Changchun New Area Industrial Investment Group, aimed at optimizing state-owned enterprise resource allocation [1] Group 1 - Longxiang Group previously held 100% of ChaoDa Group's shares, and after the transfer, it will hold 81%, while the New Area Industrial Investment Group will hold 19% [1] - Both Longxiang Group and the New Area Industrial Investment Group are ultimately controlled by the New Area State-owned Assets Supervision and Administration Bureau [1] - The change in shareholding structure does not affect the number of shares or the shareholding ratio held by the controlling shareholder, which remains ChaoDa Group, with the actual controller still being the New Area State-owned Assets Supervision and Administration Bureau [1] Group 2 - The restructuring will not impact the normal business operations of the company [1]

Core Viewpoint - Changchun Gaoxin (000661.SZ) announced a restructuring of equity holdings involving the transfer of 19% of the shares of ChaoDa Group from Longxiang Investment Holding Group to Changchun New Area Industrial Investment Group, aimed at optimizing state-owned enterprise resource allocation [1] Group 1: Equity Structure Change - Longxiang Group previously held 100% of ChaoDa Group's shares, and after the transfer, it now holds 81%, while the New Area Industrial Investment Group holds 19% [1] - Both Longxiang Group and the New Area Industrial Investment Group are ultimately controlled by the New Area State-owned Assets Supervision and Administration Bureau [1] Group 2: Impact on Company Operations - The change in the equity structure of the controlling shareholder will not affect the number of shares or the shareholding ratio held by the company [1] - The controlling shareholder remains ChaoDa Group, and the actual controller continues to be the New Area State-owned Assets Supervision and Administration Bureau [1] - The equity structure change is not expected to impact the normal business operations of the company [1]